Oncotarget

Research Papers:

Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution

Benjamin Le Calvé, Audrey Griveau, David Vindrieux, Raphaël Maréchal, Clotilde Wiel, Magali Svrcek, Johann Gout, Lamia Azzi, Léa Payen, Jérôme Cros, Christelle de la Fouchardière, Pierre Dubus, Jérôme Guitton, Laurent Bartholin, Jean-Baptiste Bachet and David Bernard _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:32100-32112. https://doi.org/10.18632/oncotarget.8527

Metrics: PDF 2434 views  |   HTML 2446 views  |   ?  


Abstract

Benjamin Le Calvé1,2,3,4,14, Audrey Griveau1,2,3,4,*, David Vindrieux1,2,3,4,*, Raphaël Maréchal5, Clotilde Wiel1,2,3,4, Magali Svrcek6,7, Johann Gout1,2,3,4, Lamia Azzi8, Léa Payen1,2,3,4,9, Jérôme Cros10,11, Christelle de la Fouchardière3, Pierre Dubus8, Jérôme Guitton4,9, Laurent Bartholin1,2,3,4, Jean-Baptiste Bachet12,13, David Bernard1,2,3,4

1Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France

2CNRS UMR5286, Lyon, France

3Centre Léon Bérard, Lyon, France

4Université de Lyon, Lyon, France

5Department of Gastroenterology and Gastrointestinal Cancer Unit, Erasme Hospital, Université Libre de Bruxelles, Belgium

6Department of Pathology, AP-HP, Hôpitaux Universitaires Est Parisien, Saint-Antoine Hospital, Paris, France

7Sorbonne University, UPMC University, Paris, France

8Service de Biologie des Tumeurs, CHU de Bordeaux Hôpital du Haut Lévêque, Pessac, France

9Hospices Civils de Lyon, Université de Lyon, Lyon, France

10AP-HP, Hôpitaux Universitaires Paris Nord Val de Seine, Beaujon, France

11Paris Diderot University, Paris, France

12Sorbonne University, UPMC University and INSERM, UMRS 1147, Paris Descrates University, Paris, France

13Gastroenterology Department, APHP, Pitié Salpêtrière Hospital, Paris, France

14Present address: URBC-NARILIS, University of Namur, Namur, Belgium

*These authors have contributed equally to this work

Correspondence to:

David Bernard, email: david.bernard@lyon.unicancer.fr

Keywords: chemoresistance, collagen, survival, biomarker, lysyl oxidase

Received: December 07, 2015     Accepted: March 18, 2016     Published: April 01, 2016

ABSTRACT

Solid tumors often display chemotherapy resistance. Pancreatic ductal adenocarcinoma (PDAC) is the archetype of resistant tumors as current chemotherapies are inefficient. The tumor stroma and extracellular matrix (ECM) are key contributors to PDAC aggressiveness and to limiting the efficacy of chemotherapy. Lysyl oxidase (LOX) family members mediate collagen cross-linking and thus promote ECM stiffening. Our data demonstrate increased LOX, LOXL1, and LOXL2 expression in PDAC, and that the level of fibrillar collagen, which is directly dependent of LOX family activity, is an independent predictive biomarker of adjuvant “Gemcitabine-based chemotherapy” benefit. Experimentally in mice, increased LOX family activity through LOXL2 promotes chemoresistance. This effect of LOX family activity seems to be due to decreased gemcitabine intra-tumoral diffusion. This observation might be explained by increased fibrillar collagen and decreased vessel size observed in tumors with increased LOX family activity. In conclusion, our data support that LOX family activity is both a novel target to improve chemotherapy as well as a novel biomarker to predict gemcitabine benefit in PDAC. Beyond the PDAC, it is possible that targeting LOX family activity might improve efficacy of chemotherapies against different kinds of solid tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8527